We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)
Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)

SEKISUI Diagnostics (Burlington, MA, USA) displayed its point-of-care rapid diagnostics and clinical chemistry reagents at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

This year’s 2021 AACC was held in partnership with the Canadian Society of Clinical Chemists (CSCC) at the Georgia World Congress Center in Atlanta, September 26-30. SEKISUI Diagnostics delivers differentiated products, instrument systems, and services that support the improvement of patient care worldwide. The company is a recognized leader in the development, manufacture, and supply of innovative clinical chemistry reagents and systems that enhance the clinical chemistry laboratory function. Over 1.7 billion tests are performed each year using the company’s products. With a broad line of >65 reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays, SEKISUI is well-poised to meet individual needs.

At AACC 2021, SEKISUI displayed its OSOM rapid diagnostics that offers a variety of family and women’s health products, and services. These diagnostic tests allow healthcare professionals to cost effectively diagnose at the point-of-care in one visit, thus reducing labor and follow-up time while increasing patient satisfaction. The company also demonstrated its Acucy System that provides clinicians with flexibility in workflow and accurate, standardized results for improved patient care.

Also on display was SEKISUI’s FastPack IP System which is a fully automated quantitative immunoassay analyzer designed for use in any size physician office laboratory and provides results in 12 minutes or less with the push of a button. Offering real-time testing with a simple three-step process, the system enables healthcare professionals to diagnose, monitor, and adjust therapy in one patient visit.

Related Links:
SEKISUI Diagnostics 

New
Gold Member
Human Chorionic Gonadotropin Test
hCG Quantitative - R012
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Alpha-Fetoprotein Reagent
AFP Reagent Kit
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.